Filed Under: Biologics, Dermatology, Immunology, Infectious Disease, Metabolic disease/endicrinology, Oncology Tagged With: AbbVie, biologic drugs, biosimilar competition, drug sales H1 2025, Eli Lilly, GLP-1 drugs, IL-23 inhibitors, immunology drugs, Keytruda patent expiry, loss of exclusivity, Merck, Novo Nordisk, obesity drugs, Oncology Therapeutics, patent cliff 2028, PD-1 inhibitors, pharmaceutical blockbusters, prescription drug market, Skyrizi, therapeutic categories Brian Buntz As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology
However, it should be avoided if diarrhea is already a problem
Thc hin cc hot ng ny t 150-300 pht mi tun, tc 30-60 pht mi ngy, c th t chy calo d tha, ci thin tun hon mu v tng cng sc khe tim mch, ng thi h tr gim cn bn vng
[1] According to the UK SmPC, all patients taking Mounjaro should be vigilant for signs of acute pancreatitis (severe abdominal pain, often radiating to the back, accompanied by vomiting) and seek urgent medical attention if these occur, even after gallbladder removal
Kind Patches marketing materials include several claims that could violate ASA guidelines: 92.3% of participants reported fewer cravings (unsubstantiated efficacy claim) Before/after style testimonials without clinical backing Implications that patches work similarly to prescription medications Claims about supporting GLP-1 production without evidence The ASA considers testimonials making medical claims as advertising, regardless of whether theyre genuine customer experiences
